



## Pauline Funchain

Associate Professor of Medicine (Oncology)  
Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Cutaneous Oncology**

900 Blake Wilbur Dr 3rd Fl  
Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 724-1445

### Bio

---

#### CLINICAL FOCUS

- Medical Oncology

#### ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute

#### ADMINISTRATIVE APPOINTMENTS

- Associate Director, Cancer Research Training and Education, Stanford Cancer Institute, (2025- present)
- Associate Program Director, Hematology and Oncology Fellowship, Stanford University, (2024- present)
- Co-Director, Immunotherapy Toxicity Program, Stanford University, (2023- present)
- Co-Director, Skin Cancer Genomics Program, Stanford University, (2023- present)

#### PROFESSIONAL EDUCATION

- Fellowship: Cleveland Clinic Foundation (2015) OH
- Fellowship: Cleveland Clinic Foundation (2012) OH
- Board Certification: Medical Oncology, American Board of Internal Medicine (2023)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2012)
- Residency: Harbor UCLA Internal Medicine Residency (2009) CA
- Medical Education: The Ohio State University Registrar (2006) OH

### Research & Scholarship

---

#### CLINICAL TRIALS

- Neoadjuvant Darovasertib in Primary Uveal Melanoma, Recruiting

- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma, Recruiting
- (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma, Not Recruiting

## Publications

---

### PUBLICATIONS

- **Chronic sequelae of immune-related adverse events.** *Expert opinion on drug safety*  
Ngo, S., Rong, J., Menon, R., Colli Cruz, C., Chatterjee, A., Mortan, R., Salim, H., Urias Rivera, A., Jafri, F. I., Garza, D., Kim, S., Funchain, P., Zhang, et al  
2026
- **Seasons of risk: Investigating temporal trends in ICI-associated Myocarditis**  
Griffith, C., Park, E., Cheng, E., McCroskey, S., Katsumoto, T., Zhu, H., Funchain, P.  
AMER ASSOC CANCER RESEARCH.2026
- **Cutaneous melanocytic mosaicism with associated melanoma: A case series.** *JAAD case reports*  
Ribaudo, I., Aldosari, E., Funchain, P., Paragh, G., Wickenheiser, M., Arbesman, J.  
2026; 68: 191-198
- **NT-17, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model.** *Scientific reports*  
Phoon, Y. P., Wolfarth, A. A., Funchain, P., Ko, J. S., Choi, D., Dedkova, E., Bateman, D. D., Corvin, J., Melenhorst, J. J., Gastman, B. R.  
2025; 15 (1): 37950
- **Tumor microRNA signatures associate with stage II/III melanoma patient outcomes.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Wiggins, J. M., Zhang, Q., Zhang, Y., Vand-Rajabpour, F., Hanniford, D., He, L., Lu, Y., Kenney, J. M., Sadeghi, K. D., Argibay, D., Orlow, I., Busam, K. J., Lezcano, et al  
2025
- **Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.** *Journal for immunotherapy of cancer*  
Zhu, L., Cheung, Y. M., Chiang, C., Gallagher, E. J., Hamnvik, O. R., Mammen, J., Quandt, Z., Jones, R., McDunn, J., Al-Bahadili, H., Angell, T., Bancos, I., Betof Warner, et al  
2025; 13 (10)
- **Germline Pathogenic Variants (gPVs) and Immune-Related Adverse Events (irAEs) in Patients with Melanoma Receiving Immune Checkpoint Inhibitors (ICI).** *Journal of the American Academy of Dermatology*  
Shen, A., Arbesman, M., Newell, D., Chen, J., Arbesman, J., Funchain, P., Kennedy, L. B.  
2025
- **Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Shatila, M., Devalaraju, S., Takigawa, K., Catinis, C., Lee, I., Baerman, E., Ngo, S., Mittal, N., Glombicki, S., Machado, A. P., Lu, L., Aleem, A. S., Thompson, et al  
2025: 1-7
- **Proceedings of the seventh annual Women in Melanoma Conference.** *Therapeutic advances in medical oncology*  
Najjar, Y. G., Orloff, M., Mitchell, T. C., Bowles, T. L., Betof Warner, A., Bollin, K., Chandra, S., Cohen, J. V., Eroglu, Z., Funchain, P., Gaughan, E., Gliitza Oliva, I., Hsu, et al  
2025; 17: 17588359251342039
- **Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*  
Joshi, U. M., Hundal, J., Mata, J. R., Schollenberger, M. D., Warriar, G., Luke, J. J., Lipson, E. J., Funchain, P.  
2025; 45 (3): e473856
- **Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) discussed at a multidisciplinary immune-related adverse event (irAE) tumor board.**

- Vandommelen, K., Brihn, L., Calabrese, C., Zhou, K., Smith, M., Abdoh, M., Kunchok, A., Philpott, J., Junna, S., Kabbur, G., Owoyemi, I., Truong, T., Gupta, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: e24112
- **Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.** *Journal for immunotherapy of cancer*  
Nassar, A. H., Abou Alaiwi, S., El Zarif, T., Denu, R., Macaron, W., Abdel-Wahab, N., Freeman, D., Vasbinder, A., Hayeck, S., Anderson, E., Goodman, R. S., Johnson, D. B., Grynberg, et al  
2025; 13 (3)
  - **Genetic Landscape of Mucosal Melanoma: Identifying Pathogenic Germline Variants.** *Pigment cell & melanoma research*  
Ribaudou, I., Arbesman, M., Ni, Y., Isaacs, J., Kennedy, L. B., Ko, J., Funchain, P., Truong, T. G., Arbesman, J.  
2025; 38 (2): e70007
  - **Germline Pathogenic Variant (gPV) Positive Patients with Melanoma Exhibit Improved Response to Checkpoint Inhibitor Immunotherapy.** *The Journal of investigative dermatology*  
Shen, A., Arbesman, M., Lodha, R., Rayman, P., Gastman, B., Ko, J., Truong, T. G., Diaz-Montero, C. M., Ni, Y., Funchain, P., Arbesman, J.  
2025
  - **Patterns in progression from early-stage melanoma to late-stage melanoma: implications for survivorship follow-up.** *Melanoma management*  
Savage, D. J., Switzer, B., Parikh, R., Song, J. M., Stanek, C., Arbesman, J., Kennedy, L. B., Funchain, P.  
2024; 11 (1): 2424708
  - **Retrospective analysis of immunotherapy outcomes in Black patients.** *The Lancet. Oncology*  
Reynolds, K. L., Funchain, P.  
2024
  - **DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.** *JCO precision oncology*  
Conway, K., Edmiston, S. N., Vondras, A., Reiner, A., Corcoran, D. L., Shen, R., Parrish, E. A., Hao, H., Lin, L., Kenney, J. M., Illelabo, G., Kostrzewa, C. E., Kuan, et al  
2024; 8: e2400375
  - **Long-term cardiovascular outcomes of immune checkpoint inhibitor-related myocarditis: A large single-centre analysis.** *ESC heart failure*  
Braghieri, L., Gharaibeh, A., Nkashama, L., Abushouk, A., Abushawer, O., Mehdizadeh-Shrifi, A., Honnekeri, B., Calabrese, C., Menon, V., Funchain, P., Collier, P., Sadler, D., Moudgil, et al  
2024
  - **How Many Doses of Infliximab Should Be Used in Immune Checkpoint Inhibitor-Induced Colitis? - A Retrospective Study**  
Kundu, R., Chatterjee, A., Zabor, E., Isaacs, J., Truong, T., Sleiman, J., Funchain, P., Philpott, J., Kennedy, L.  
LIPPINCOTT WILLIAMS & WILKINS.2024: S812-S813
  - **Real-world outcomes of patients with resected stage III melanoma treated with adjuvant therapies** *CANCER MEDICINE*  
Dima, D., Lopetegui-Lia, N., Ogbue, O., Osantowski, B., Ullah, F., Jia, X., Song, J., Gastman, B., Isaacs, J., Kennedy, L., Funchain, P.  
2024; 13 (12)
  - **TripleOverlap syndrome (TMOS): Evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database**  
Naqash, A., Abushukair, H., Alghamdi, E., Laharwal, M., Gundroo, H. M., Tan, A., Funchain, P., Abdel-Wahab, N., Sharon, E., Johnson, D., Nassar, A., Al-Harbi, F. F.  
LIPPINCOTT WILLIAMS & WILKINS.2024
  - **Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.** *Journal for immunotherapy of cancer*  
Phoon, Y. P., Lopes, J. E., Pfannenstiel, L. W., Marcela Diaz-Montero, C., Tian, Y. F., Ernstoff, M. S., Funchain, P., Ko, J. S., Winkquist, R., Losey, H. C., Melenhorst, J. J., Gastman, B. R.  
2024; 12 (4)
  - **Germline Cancer Susceptibility in Individuals with Melanoma.** *Journal of the American Academy of Dermatology*  
Funchain, P., Ni, Y., Heald, B., Bungo, B., Arbesman, M., Behera, T. R., McCormick, S., Song, J. M., Kennedy, L. B., Nielsen, S. M., Esplin, E. D., Nizialek, E., Ko, et al

2024

- **Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma**  
Kirane, A., Lee, D., Ahmad, M., Sharma, S., Serasanambati, M., Lowe, M., Applebee, C., Safrygina, E., Swetter, S., Reddy, S., Warner, A., Funchain, P., Wang, et al  
SPRINGER.2024: S33-S34
- **Clinical and Immunologic Features of Germline Pathogenic Variant (gPV) Positive Patients with Melanoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Shen, A., Arbesman, M., Lodha, R., Rayman, P., Bungo, B., Ni, Y., Chan, T., Gastman, B., Ko, J., Diaz-Montero, C. M., Arbesman, J., Funchain, P.  
2023
- **MC1R signaling through the cAMP-CREB/ATF-1 and ERK-NFκB pathways accelerates G1/S transition promoting breast cancer progression.** *NPJ precision oncology*  
Chelakkot, V. S., Thomas, K., Romigh, T., Fong, A., Li, L., Ronen, S., Chen, S., Funchain, P., Ni, Y., Arbesman, J.  
2023; 7 (1): 85
- **Systemic Therapy for Melanoma: ASCO Guideline Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Seth, R., Agarwala, S. S., Messersmith, H., Alluri, K. C., Ascierto, P. A., Atkins, M. B., Bollin, K., Chacon, M., Davis, N., Faries, M. B., Funchain, P., Gold, J. S., Guild, et al  
2023: JCO2301136
- **Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center.** *The oncologist*  
Farha, N., Faisal, M. S., Allende, D. S., Sleiman, J., Shah, R., Farha, N., Funchain, P., Philpott, J. R.  
2023; 28 (8): 706-713
- **Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
El Zarif, T., Nassar, A. H., Adib, E., Fitzgerald, B. G., Huang, J., Mouhieddine, T. H., Rubinstein, P. G., Nonato, T., McKay, R. R., Li, M., Mittra, A., Owen, D. H., Baiocchi, et al  
2023; 41 (21): 3712-3723
- **Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.** *Journal of Cancer*  
Liu, C., Shatila, M., Mathew, A., Machado, A. P., Thomas, A., Zhang, H. C., Thomas, A. S., Faleck, D., Funchain, P., Philpott, J., Grivas, P., Obeid, M., Carbonnel, et al  
2023; 14 (10): 1913-1919
- **Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality.** *European journal of neurology*  
Yan, C., Huang, M., Swetlik, C., Toljan, K., Mahadeen, A. Z., Bena, J., Kunchok, A., Funchain, P., McGinley, M.  
2023
- **Melanoma body site distribution: Germline genetics may have a lesser role.** *JAAD international*  
Decosma, L., Ni, Y., Funchain, P., Arbesman, J.  
2023; 11: 220-221
- **Reincarnating autoimmunity: Immune-related adverse events as new diseases.** *Cleveland Clinic journal of medicine*  
Funchain, P.  
2023; 90 (5): 318-319
- **InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma.** *PLoS one*  
Orlow, I., Sadeghi, K. D., Edmiston, S. N., Kenney, J. M., Lezcano, C., Wilmott, J. S., Cust, A. E., Scolyer, R. A., Mann, G. J., Lee, T. K., Burke, H., Jakrot, V., Shang, et al  
2023; 18 (4): e0269324
- **Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.** *JAMA oncology*

- Unger, J. M., Darke, A., Othus, M., Truong, T. G., Khushalani, N., Kendra, K., Lewis, K. D., Faller, B., Funchain, P., Buchbinder, E. I., Tarhini, A. A., Kirkwood, J. M., Sharon, et al  
2023; 9 (2): 251-260
- **Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series.** *Cancer medicine*  
Longinow, J., Zmaili, M., Skoza, W., Kondoleon, N., Marquardt, R., Calabrese, C., Funchain, P., Moudgil, R.  
2023; 12 (3): 2281-2289
  - **Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Atkins, M. B., Lee, S. J., Chmielowski, B., Tarhini, A. A., Cohen, G. I., Truong, T. G., Moon, H. H., Davar, D., O'Rourke, M., Stephenson, J. J., Curti, B. D., Urba, W. J., Brell, et al  
2023; 41 (2): 186-197
  - **Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.** *Pigment cell & melanoma research*  
Luo, L., Shen, R., Arora, A., Orlov, I., Busam, K. J., Lezcano, C., Lee, T. K., Hernando, E., Gorlov, I., Amos, C., Ernstoff, M. S., Seshan, V. E., Cust, et al  
2022; 35 (6): 605-612
  - **A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations.** *Future oncology (London, England)*  
Rodón, J., Funchain, P., Laetsch, T. W., Arkenau, H. T., Hervieu, A., Singer, C. F., Murciano-Goroff, Y. R., Chawla, S. P., Anthony, K., Yamamiya, I., Liu, M., Halim, A. B., Benhadji, et al  
2022; 18 (30): 3377-3387
  - **Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.** *Targeted oncology*  
Sheng, I. Y., Gupta, S., Reddy, C. A., Angelini, D., Funchain, P., Sussman, T. A., Sleiman, J., Ornstein, M. C., McCrae, K., Khorana, A. A.  
2022; 17 (5): 563-569
  - **Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.** *Journal for immunotherapy of cancer*  
Sussman, T. A., Knackstedt, R., Wei, W., Funchain, P., Gastman, B. R.  
2022; 10 (8)
  - **Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Seth, R., Messersmith, H., Funchain, P.  
2022; 40 (21): 2375-2377
  - **ss-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma**  
Switzer, B., Pandey, M. R., Valentine, A., Witkiewicz, A., Knudsen, E., Attwood, K., Tario, J., Funchain, P., Drabick, J. J., Mohammadpour, H., Ernstoff, M. S., Puzanov, I., Repasky, et al  
AMER ASSOC CANCER RESEARCH.2022
  - **Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report.** *Frontiers in oncology*  
Behera, T. R., Song, J. M., Ko, J., Eicher, D., Arbesman, J., Gastman, B., Farkas, D. H., Funchain, P.  
2022; 12: 846187
  - **Germline predisposition in oncologic and dermatologic melanoma cohorts.**  
Funchain, P., Ni, Y., Bungo, B., Heald, B., Arbesman, M., Behera, T., Nielsen, S. M., McCormick, S., Song, J., Nizialek, E., Gastman, B., Esplin, E. D., Artomov, et al  
LIPPINCOTT WILLIAMS & WILKINS.2022
  - **Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival.** *Gastroenterology research*  
Alomari, M., Al Ashi, S., Chadalavada, P., Khazaaleh, S., Covut, F., Al Momani, L., Elkafrawy, A., Padbidri, V., Funchain, P., Campbell, D., Romero-Marrero, C.  
2022; 15 (2): 56-66
  - **Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.** *Cancer discovery*

- Grossmann, K. F., Othus, M., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., Petrella, T. M., Truong, T. G., Khushalani, N. I., Cohen, J. V., Buchbinder, E. I., Kendra, K., Funchain, et al  
2022; 12 (3): 644-653
- **A high OXPPOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients.** *The Journal of experimental medicine*  
Li, C., Phoon, Y. P., Karlinsey, K., Tian, Y. F., Thapaliya, S., Thongkum, A., Qu, L., Matz, A. J., Cameron, M., Cameron, C., Menoret, A., Funchain, P., Song, et al  
2022; 219 (1)
  - **Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Schneider, B. J., Naidoo, J., Santomaso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, et al  
2021; 39 (36): 4073-4126
  - **Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Santomaso, B. D., Nastoupil, L. J., Adkins, S., Lacchetti, C., Schneider, B. J., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, et al  
2021; 39 (35): 3978-3992
  - **Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.** *Targeted oncology*  
Sheng, I. Y., Gupta, S., Reddy, C. A., Angelini, D., Funchain, P., Sussman, T. A., Sleiman, J., Ornstein, M. C., McCrae, K., Khorana, A. A.  
2021; 16 (6): 813-821
  - **Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms.** *Frontiers in cardiovascular medicine*  
Rikhi, R., Karnuta, J., Hussain, M., Collier, P., Funchain, P., Tang, W. H., Chan, T. A., Moudgil, R.  
2021; 8: 721333
  - **Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.** *Journal for immunotherapy of cancer*  
Sleiman, J., Wei, W., Shah, R., Faisal, M. S., Philpott, J., Funchain, P.  
2021; 9 (6)
  - **Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.** *Med (New York, N.Y.)*  
Roopkumar, J., Swaidani, S., Kim, A. S., Thapa, B., Gervaso, L., Hobbs, B. P., Wei, W., Alban, T. J., Funchain, P., Kundu, S., Sangwan, N., Rayman, P., Pavicic, et al  
2021; 2 (4): 423-434
  - **Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.** *Journal for immunotherapy of cancer*  
Sussman, T. A., Li, H., Hobbs, B., Funchain, P., McCrae, K. R., Khorana, A. A.  
2021; 9 (1)
  - **Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Gandhi, S., Pandey, M. R., Attwood, K., Ji, W., Witkiewicz, A. K., Knudsen, E. S., Allen, C., Tario, J. D., Wallace, P. K., Cedeno, C. D., Levis, M., Stack, S., Funchain, et al  
2021; 27 (1): 87-95
  - **Clinical Trials in Metastatic Uveal Melanoma: Current Status.** *Ocular oncology and pathology*  
Sussman, T. A., Funchain, P., Singh, A.  
2020; 6 (6): 381-387
  - **Systemic Therapy for Melanoma: ASCO Guideline.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Seth, R., Messersmith, H., Kaur, V., Kirkwood, J. M., Kudchadkar, R., McQuade, J. L., Provenzano, A., Swami, U., Weber, J., Alluri, K. C., Agarwala, S., Ascierto, P. A., Atkins, et al  
2020; 38 (33): 3947-3970
  - **Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy**

Sheng, I., Gupta, S., Reddy, C. A., Angelini, D. E., Funchain, P., Roopkumar, J., Sussman, T. A., Sleiman, J., Gilligan, T. D., Ornstein, M. C., Khorana, A. A.  
AMER SOC HEMATOLOGY.2020

- **INCIDENCE OF THROMBOEMBOLISM (TE) IN PATIENTS WITH MELANOMA RECEIVING IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY AND ITS ADVERSE IMPACT ON SURVIVAL**  
Sussman, T., Roopkumar, J., Li, H., McCrae, K., Funchain, P., Khorana, A.  
BMJ PUBLISHING GROUP.2020: A390-A391
- **SURVIVAL OUTCOMES AND TOXICITY AMONG PATIENTS TREATED WITH CONCOMITANT RADIOTHERAPY AND IMMUNOTHERAPY FOR ADVANCED MELANOMA: TWO FACES OF THE ABCOPAL EFFECT?**  
Andreatos, N., Roopkumar, J., Khorana, A., Woody, N., Gastman, B., Funchain, P.  
BMJ PUBLISHING GROUP.2020: A116
- **OUTCOMES OF STAGE IV MELANOMA IN THE ERA OF IMMUNOTHERAPY: A NATIONAL CANCER DATABASE (NCDB) ANALYSIS**  
Sussman, T., Wei, W., Funchain, P., Gastman, B.  
BMJ PUBLISHING GROUP.2020: A133-A134
- **Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report From a Major Tertiary Care Center**  
Faisal, M., Sleiman, J., Shah, R. S., Funchain, P., Philpott, J.  
LIPPINCOTT WILLIAMS & WILKINS.2020: S679-S680
- **Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database. *Melanoma research***  
Conic, R. R., Knackstedt, R., Sussman, T. A., Rambhia, S., Damiani, G., Funchain, P., Ko, J., Gastman, B. R.  
2020; 30 (4): 376-385
- **Targeted next generation sequencing (NGS) to classify melanocytic neoplasms. *Journal of cutaneous pathology***  
Zarabi, S. K., Azzato, E. M., Tu, Z. J., Ni, Y., Billings, S. D., Arbesman, J., Funchain, P., Gastman, B., Farkas, D. H., Ko, J. S.  
2020; 47 (8): 691-704
- **Increased normal tissue telomere length is associated with decreased survival in melanoma patients**  
Ni, Y., Romigh, T., Funchain, P., Arbesman, J.  
ELSEVIER SCIENCE INC.2020: S17
- **Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study. *JNCI cancer spectrum***  
Klek, S., Heald, B., Milinovich, A., Ni, Y., Abraham, J., Mahdi, H., Estfan, B., Khorana, A. A., Bolwell, B. J., Grivas, P., Sohal, D. P., Funchain, P.  
2020; 4 (3): pkaa018
- **Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. *Journal for immunotherapy of cancer***  
Najjar, Y. G., Navrazhina, K., Ding, F., Bhatia, R., Tsai, K., Abbate, K., Durden, B., Eroglu, Z., Bhatia, S., Park, S., Chowdhary, A., Chandra, S., Kennedy, et al  
2020; 8 (1)
- **Real-world experience of talimogene laherparepvec in patients receiving immunotherapy in metastatic melanoma.**  
Behera, T., Song, J., Ko, J. S., McNamara, M. J., Funchain, P., Gastman, B.  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Patterns in progression from early stage melanoma to late stage melanoma: Implications for survivorship follow up.**  
Switzer, B., Savage, D., Song, J., Stanek, C., Funchain, P.  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **A phase II trial of nivolumab in combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness.**  
Sussman, T. A., Wei, W., Hobbs, B., Diaz-Montero, C., Ni, Y., Arbesman, J., Ko, J. S., Gastman, B., Funchain, P.  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Role of glutamine metabolism in CD8<sup>+</sup>PD-1<sup>+</sup>TIM-3<sup>+</sup> T cells in ICI resistant melanoma.**  
Thapaliya, S., Gastman, B., Phoon, Y., Li, C., Zhou, B., Funchain, P., Richardson, B., Cameron, M., Cameron, C.  
LIPPINCOTT WILLIAMS & WILKINS.2020

- **Immune-mediated adverse events following concomitant radiotherapy and immunotherapy in patients with melanoma and Merkel cell carcinoma: A preliminary report from an evolving retrospective registry.**  
Andreatos, N., Roopkumar, J., Khorana, A. A., Funchain, P.  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Thromboembolism (TE) in patients (pts) with bladder cancer treated with checkpoint inhibitors (CPIs).**  
Sheng, I., Gupta, S., Reddy, C. A., Angelini, D. E., Funchain, P., Sussman, T. A., Sleiman, J., Gilligan, T. D., Ornstein, M., Khorana, A. A.  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **CMV coinfection in treatment refractory immune checkpoint inhibitor colitis. *BMJ case reports***  
Harris, K. B., Funchain, P., Baggott, B. B.  
2020; 13 (5)
- **SINGLE CELL TRANSCRIPTOME ANALYSIS IDENTIFIES UNIQUE FEATURES IN CIRCULATING CD8+T CELLS THAT CAN PREDICT IMMUNOTHERAPY RESPONSE IN MELANOMA PATIENTS**  
Li, C., Phoon, Y., Karlinsey, K., Tian, Y., Thapaliya, S., Qu, L., Cameron, M., Cameron, C., Menoret, A., Funchain, P., Song, J., Diaz-Montero, C., Rodriguez, et al  
BMJ PUBLISHING GROUP.2020: A5
- **Prognosis of patients developing immune-related adverse events with immune checkpoint inhibitors in melanoma influenced by the ability to resume therapy**  
Song, J., Behera, T., Demski, K., Yurco, A., Patil, P., Funchain, P.  
AMER SOC CLINICAL ONCOLOGY.2020
- **Venous thromboembolism (VTE) in melanoma patients (pts) on immunotherapy (IO)**  
Sussman, T. A., Roopkumar, J., Li, H., Hobbs, B., Khorana, A. A., Funchain, P.  
AMER SOC CLINICAL ONCOLOGY.2020
- **Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels. *JCO precision oncology***  
Akras, Z., Bungo, B., Leach, B. H., Marquard, J., Ahluwalia, M., Carraway, H., Grivas, P., Sohal, D. P., Funchain, P.  
2019; 3: 1-11
- **Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade**  
Swaidani, S., Roopkumar, J., Jun-Shim, Y., Charles, C., Paul, S., Kundu, S., Funchain, P., Rayman, P., Pavicic, P. G., Diaz-Montero, C., Khorana, A. A., McCrae, K. R.  
AMER SOC HEMATOLOGY.2019
- **IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES**  
Lauko, A., Ali, A., Sagar, S., Barnett, A., Li, H., Chao, S., Stevens, G., Pennell, N., Peereboom, D., Yu, J., Murphy, E., Angelov, L., Funchain, et al  
OXFORD UNIV PRESS INC.2019: 55
- **Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology***  
Abu-Sbeih, H., Ali, F. S., Naqash, A. R., Owen, D. H., Patel, S., Otterson, G. A., Kendra, K., Ricciuti, B., Chiari, R., De Giglio, A., Sleiman, J., Funchain, P., Wills, et al  
2019; 37 (30): 2738-2745
- **Immune Checkpoint Inhibitor Related Colitis (ICI-Colitis) in Patients With Preexisting Inflammatory Bowel Disease or Microscopic Colitis**  
Sleiman, J., Shah, R., Wei, W., Funchain, P., Philpott, J., Simons-Linares, R.  
LIPPINCOTT WILLIAMS & WILKINS.2019: S393
- **Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node utilization, positivity and effects on overall survival**  
Conic, R., Ko, J., Damiani, G., Funchain, P., Vidimos, A., Gastman, B.  
MOSBY-ELSEVIER.2019: AB122
- **Comparison of head and neck and nonehead and neck Merkel cell carcinoma: Clinicopathologic characteristics, time to treatment initiation, and survival**  
Conic, R., Ko, J., Damiani, G., Funchain, P., Vidimos, A., Gastman, B.  
MOSBY-ELSEVIER.2019: AB36

- **Variations of Diagnosis and Management of Immune Checkpoint Inhibitor Pancreatic Injury (ICIPI) and Immune Checkpoint Inhibitor Pancreatitis: A Single Institution Experience**  
Shah, R., Sleiman, J., Simons-Linares, R., Faisal, M., Song, J., Philpott, J., Funchain, P.  
LIPPINCOTT WILLIAMS & WILKINS.2019: S58
- **Immune Checkpoint Inhibitors-Related Gastrointestinal Toxicity Is Associated With Better Overall Survival and Treatment Response in Cancer Patients**  
Alomari, M., Al Ashi, S., Al Momani, L., Nehme, F., Sarmini, M., Young, M., Funchain, P., Romero-Marrero, C.  
LIPPINCOTT WILLIAMS & WILKINS.2019: S552-S553
- **The paradox of melanoma in oculocutaneous albinism: A case report and literature review**  
Ravichandran, S., Funchain, P., Arbesman, J.  
ELSEVIER SCIENCE INC.2019: B21
- **Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases** *ANNALS OF ONCOLOGY*  
Knackstedt, R., Sussman, T. A., McCahon, L., Song, J., Funchain, P., Gastman, B.  
2019; 30 (8): 1399-1400
- **Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node positivity and association with overall survival.** *Journal of the American Academy of Dermatology*  
Conic, R. R., Ko, J., Saridakis, S., Damiani, G., Funchain, P., Vidimos, A., Gastman, B. R.  
2019; 81 (2): 364-372
- **Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes.** *Ocular oncology and pathology*  
Xu, L. T., Funchain, P. F., Bena, J. F., Li, M., Tarhini, A., Berber, E., Singh, A. D.  
2019; 5 (5): 323-332
- **Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials (vol 125, pg 18, 2019)** *CANCER*  
Jeter, J. M., Bowles, T. L., Curiel-Lewandrowski, C., Swetter, S. M., Filipp, F. V., Abdel-Malek, Z. A., Geskin, L. J., Brewer, J. D., Arbiser, J. L., Gershenwald, J. E., Chu, E. Y., Kirkwood, J. M., Box, et al  
2019; 125 (15): 2706
- **Immune Checkpoint Inhibitors Associated with Cardiotoxicity in Cancer Patients: A Large Single-Center Experience**  
Chahine, J., Thapa, B., Ala, C. K., Patil, P., Funchain, P., Maroo, A., Klein, A. L., Tang, W.  
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2019: S63
- **Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies.**  
Conces, M., Ni, Y., Bazeley, P., Patel, B., Funchain, P., Carraway, H. E.  
AMER SOC CLINICAL ONCOLOGY.2019
- **Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).**  
Thapa, B., Roopkumar, J., Kim, A. S., Gervaso, L., Patil, P., Calabrese, C., Khorana, A. A., Funchain, P.  
AMER SOC CLINICAL ONCOLOGY.2019
- **Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.**  
Abu-Sbeih, H., Ali, F., Naqash, A., Owen, D., Patel, S. H., Otterson, G., Kendra, K., Ricciuti, B., Chiari, R., De Giglio, A., Sleiman, J., Funchain, P., Beatriz, et al  
AMER SOC CLINICAL ONCOLOGY.2019
- **Prognostic Significance of "Nonsolid" Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes.** *The American journal of surgical pathology*  
Erstine, E. M., Tetzlaff, M. T., Jia, X., Aung, P. P., Prieto, V. G., Funchain, P., Gastman, B. R., Billings, S. D., Ko, J. S.  
2019
- **Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.**  
Diaz-Montero, C., Ravichandran, S., Pavicic, P. G., Rayman, P. A., Tannenbaum, C., Finke, J., Ko, J. S., Funchain, P., Tarhini, A. A.  
AMER SOC CLINICAL ONCOLOGY.2019
- **THE MICROBIOME OF TEMPORAL ARTERIES**

- Hoffman, G. S., Getz, T. M., Padmanabhan, R., Villa-Forte, A., Calabrese, L. H., Clifford, A. H., Funchain, P., Sankhunmy, M., Perry, J. D., Blandford, A., Kosmorsky, G., Lystad, L., Eng, et al  
OXFORD UNIV PRESS.2019
- **Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated Melanoma.** *The American Journal of dermatopathology*  
Ko, J. S., Gastman, B. R., Conic, R., Tellez Diaz Trujillo, A., Diaz-Montero, C. M., Billings, S. D., Tarhini, A., Funchain, P., Atanaskova Mesinkovska, N.  
2019; 41 (3): 180-187
  - **The Microbiome of Temporal Arteries.** *Pathogens & immunity*  
Hoffman, G. S., Getz, T. M., Padmanabhan, R., Villa-Forte, A., Clifford, A. H., Funchain, P., Sankunmy, M., Perry, J. D., Blandford, A., Kosmorsky, G., Lystad, L., Calabrese, L. H., Eng, et al  
2019; 4 (1): 21-38
  - **A multi-institutional study assessing prevalence of deleterious germline mutations in pancreatic cancer**  
Sadaps, M., Funchain, P., Heald, B., Huether, R., Pitt, J., White, K., Khorana, A. A., Sohal, D.  
AMER SOC CLINICAL ONCOLOGY.2019
  - **Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database.** *Journal of the American Academy of Dermatology*  
Conic, R. R., Ko, J., Damiani, G., Funchain, P., Knackstedt, T., Vij, A., Vidimos, A., Gastman, B. R.  
2019; 80 (2): 441-447
  - **Immune Check Point Inhibitor-Associated Glomerulonephritis.** *Kidney international reports*  
Ashour, T., Nakhoul, G., Patil, P., Funchain, P., Herlitz, L.  
2019; 4 (2): 355-359
  - **Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials** *CANCER*  
Jeter, J. M., Bowles, T. L., Curiel-Lewandrowski, C., Swetter, S. M., Filipp, F. V., Abdel-Malek, Z. A., Geskin, L. J., Brewer, J. D., Arbiser, J. L., Gershenwald, J. E., Chu, E. Y., Kirkwood, J. M., Box, et al  
2019; 125 (1): 18-44
  - **Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash.** *The oncologist*  
Patil, P. D., Fernandez, A. P., Velcheti, V., Tarhini, A., Funchain, P., Rini, B., Khasawneh, M., Pennell, N. A.  
2019; 24 (1): 4-8
  - **Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience.** *JCO precision oncology*  
Sadaps, M., Funchain, P., Mahdi, H., Grivas, P., Pritchard, A., Klek, S., Estfan, B., Abraham, J., Budd, G. T., Stevenson, J. P., Pennell, N. A., Khorana, A. A., Bolwell, et al  
2018; 2: 1-11
  - **Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Johnson, D. B., Bordeaux, J., Kim, J. Y., Vaupel, C., Rimm, D. L., Ho, T. H., Joseph, R. W., Daud, A. I., Conry, R. M., Gaughan, E. M., Hernandez-Aya, L. F., Dimou, A., Funchain, et al  
2018; 24 (21): 5250-5260
  - **The Impact of a Novel Immune Related Adverse Event Tumor Board on Interprofessional Clinical Confidence and Collaboration**  
Calabrese, C., Funchain, P., Patil, P. D., Calabrese, L. H.  
WILEY.2018
  - **How should we diagnose and manage checkpoint inhibitor-associated colitis?** *Cleveland Clinic journal of medicine*  
Khan, F., Funchain, P., Bennett, A., Hull, T. L., Shen, B.  
2018; 85 (9): 679-683
  - **Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations.** *Pigment cell & melanoma research*  
Arbesman, J., Ravichandran, S., Funchain, P., Thompson, C. L.  
2018; 31 (4): 529-533

- **Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.** *Journal of neurosurgery*  
Kotecha, R., Miller, J. A., Venur, V. A., Mohammadi, A. M., Chao, S. T., Suh, J. H., Barnett, G. H., Murphy, E. S., Funchain, P., Yu, J. S., Vogelbaum, M. A., Angelov, L., Ahluwalia, et al  
2018; 129 (1): 50-59
- **Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic.**  
Sadaps, M., Funchain, P., Mahdi, H., Grivas, P., Pritchard, A., Klek, S., Estfan, B. N., Abraham, J., Budd, G., Stevenson, J., Pennell, N. A., Khorana, A. A., Bolwell, et al  
AMER SOC CLINICAL ONCOLOGY.2018
- **Germline variants from paired somatic-germline testing in pancreatic cancer.**  
Funchain, P., Heald, B., White, K., Buschmann, M., Roggin, K. K., Khorana, A. A., Sohal, D.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB).**  
Klek, S., Heald, B., Milinovich, A., Ni, Y., Abraham, J., Grivas, P., Mahdi, H., Khorana, A. A., Bolwell, B., Sohal, D., Funchain, P.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Multiplex germline testing in selected melanomas presenting to oncology clinic**  
Funchain, P., Heald, B., Song, J., Nizialek, E., Marquard, J., McNamara, M. J., Tarhini, A. A., Gastman, B., Arbesman, J.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.** *Journal for immunotherapy of cancer*  
Sun, L., Funchain, P., Song, J. M., Rayman, P., Tannenbaum, C., Ko, J., Mcnamara, M., Marcela Diaz-Montero, C., Gastman, B.  
2018; 6 (1): 36
- **Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma.** *Journal of the American Academy of Dermatology*  
Stiegel, E., Xiong, D., Ya, J., Funchain, P., Isakov, R., Gastman, B., Vij, A.  
2018; 78 (5): 942-948
- **Posterior Reversible Encephalopathy Syndrome during Treatment with Lenvatinib**  
Khoury, J., Funchain, P.  
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Shared medical appointment for early stage melanoma survivorship**  
Funchain, P., Song, J., Stanek, C., McNamara, M. J., Tarhini, A. A., Gastman, B., Marcus, J.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Using Genomic Sequencing to Improve Management in Melanoma** *ONCOLOGY-NEW YORK*  
Funchain, P., Tarhini, A. A.  
2018; 32 (3): 98-+
- **Single center experience of dermatologic and oncologic surveillance patterns for late stage melanomas that progressed from early stage melanoma.**  
Song, J., Marcus, J., Stanek, C., McNamara, M. J., Gastman, B., Tarhini, A. A., Funchain, P.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes**  
Mendiratta, P., Loehr, A., Simmons, A., Barata, P. C., Klek, S., Pritchard, A., Enamekhoo, H., Funchain, P., Sohal, D., Ali, S., Gilligan, T. D., Ornstein, M., Garcia, et al  
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series**  
Sun, L., Funchain, P., Song, J., McNamara, M., Gastman, B.  
BMC.2017

- **Outcomes Following Spine Stereotactic Radiosurgery for the Treatment of Melanoma Spine Metastases**  
Tom, M. C., Yang, K., Balagamwala, E. H., Angelov, L., Mohammadi, A. M., McNamara, M., Funchain, P., Suh, J. H., Chao, S. T.  
ELSEVIER SCIENCE INC.2017: E528
- **Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance** *ANNALS OF ONCOLOGY*  
Barata, P. C., Koshkin, V. S., Funchain, P., Sohal, D., Pritchard, A., Klek, S., Adamowicz, T., Gopalakrishnan, D., Garcia, J., Rini, B., Grivas, P.  
2017; 28 (10): 2458-2463
- **Changing Treatment Paradigms for Brain Metastases From Melanoma PART 2: When and How to Use the New Systemic Agents** *ONCOLOGY-NEW YORK*  
Venur, V., Funchain, P., Kotecha, R., Chao, S. T., Ahluwalia, M. S.  
2017; 31 (9): 659-667
- **Changing Treatment Paradigms for Brain Metastases From Melanoma** *ONCOLOGY-NEW YORK*  
Venur, V., Funchain, P., Kotecha, R., Chao, S. T., Ahluwalia, M. S.  
2017; 31 (8): 602-606
- **Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma.** *BBA clinical*  
Mukherjee, P. K., Funchain, P., Retuerto, M., Jurevic, R. J., Fowler, N., Burkey, B., Eng, C., Ghannoum, M. A.  
2017; 7: 8-15
- **Precision oncology experience at a tertiary care center.**  
Sadaps, M., Funchain, P., Grivas, P., Estfan, B. N., Abraham, J., Stevenson, J., Pennell, N. A., Khorana, A. A., Bolwell, B., Sohal, D.  
AMER SOC CLINICAL ONCOLOGY.2017
- **Single-center experience of PD1 inhibition in metastatic uveal melanoma.**  
Xu, T., Song, J., McNamara, M. J., Gastman, B., Singh, A. D., Funchain, P.  
AMER SOC CLINICAL ONCOLOGY.2017
- **Flow cytometric detection of MDSC populations in unfractionated blood.**  
Diaz-Montero, C., Rayman, P. A., Kim, J., Pavicic, P. G., Tannenbaum, C., Velcheti, V., Funchain, P., Ko, J. S., Grivas, P., Rini, B. I., Montero, A. J., Finke, J.  
AMER SOC CLINICAL ONCOLOGY.2017
- **Do patients learn from survivorship care plans?**  
Bodmann, J., Harr, B., Rybicki, L. A., Koyfman, S. A., Geiger, J., Funchain, P., Joshi, N., Woody, N., Ives, D. I., Hamker, J. F., Adelstein, D. J.  
AMER SOC CLINICAL ONCOLOGY.2017
- **Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas.** *Genome medicine*  
Wang, H., Funchain, P., Bebek, G., Altemus, J., Zhang, H., Niazi, F., Peterson, C., Lee, W. T., Burkey, B. B., Eng, C.  
2017; 9 (1): 14
- **Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients.** *Carcinogenesis*  
Ragin, C., Liu, J. C., Jones, G., Shoyele, O., Sowunmi, B., Kennett, R., Groen, H. J., Gibbs, D., Blackman, E., Esan, M., Brandwein, M. S., Devarajan, K., Bussu, et al  
2017; 38 (2): 218-229
- **Strategies for clinical implementation of screening for hereditary cancer syndromes.** *Seminars in oncology*  
Heald, B., Marquard, J., Funchain, P.  
2016; 43 (5): 609-614
- **Clinical predictive factors of overall survival and locoregional failure in advanced laryngeal cancer treated with definitive chemoradiation.**  
Khan, A. M., Ward, M. C., Adelstein, D. J., Koyfman, S. A., Reddy, C. A., Bhateja, P., Funchain, P., Lamarre, E., Burkey, B., Khan, M., Scharpf, J., Prendes, B., Greskovich, et al  
AMER SOC CLINICAL ONCOLOGY.2016
- **Clinical Predictors of Locoregional Failure in Advanced Laryngeal Cancer Treated With Definitive Chemotherapy and Radiation**  
Khan, A. M., Ward, M. C., Adelstein, D. J., Koyfman, S., Reddy, C. A., Bhateja, P., Funchain, P., Lamarre, E., Burkey, B. B., Khan, M., Scharpf, J., Prendes, B., Greskovich, et al

ELSEVIER SCIENCE INC.2016: 902

- **Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.** *Journal of oncology practice*  
Hong, S., Funchain, P., Haddad, A., Crowe, J., Dalpiaz, N., Abraham, J.  
2016; 12 (3): 270-2
- **Prospective Clinical Study of Precision Oncology in Solid Tumors.** *Journal of the National Cancer Institute*  
Sohal, D. P., Rini, B. I., Khorana, A. A., Dreicer, R., Abraham, J., Procop, G. W., Saunthararajah, Y., Pennell, N. A., Stevenson, J. P., Pelley, R., Estfan, B., Shepard, D., Funchain, et al  
2015; 108 (3)
- **Comprehensive Functional Genomic Profiling of HPV Unassociated Head and Neck Squamous Cell Cancer Identifies Neomorphic Mutations That Confer Resistance to Therapy**  
Kittel, J., Funchain, P., Chute, D., Woody, N. M., Hammerman, P., Koyfman, S., Abazeed, M.  
ELSEVIER SCIENCE INC.2015: E538
- **Prospective clinical study of precision oncology in solid tumors**  
Sohal, D., Rini, B. I., Khorana, A. A., Dreicer, R., Abraham, J., Procop, G., Saunthararajah, Y., Pennell, N. A., Stevenson, J., Pelley, R., Estfan, B. N., Shepard, D., Funchain, et al  
AMER SOC CLINICAL ONCOLOGY.2015
- **Hereditary implications of somatic tumor testing**  
Funchain, P., Sohal, D., Khorana, A. A., Abraham, J., Pennell, N. A., Rini, B. I., Dreicer, R., Bolwell, B., Eng, C.  
AMER SOC CLINICAL ONCOLOGY.2015
- **Temporal Artery Microbiome in Giant Cell Arteritis.**  
Clifford, A., Funchain, P., Lystad, L., Peterson, C., Altemus, J., Hoffman, G. S., Eng, C.  
WILEY-BLACKWELL.2014: S343
- **Microbiomes of Inflammatory and Non-Inflammatory Thoracic Aortic Aneurysms.**  
Funchain, P., Hoffman, G. S., Svensson, L., Roselli, E., Pettersson, G., Johnston, D., Soltesz, E., Chakravarti, R., Clifford, A., Eng, C.  
WILEY-BLACKWELL.2014: S37
- **Hunting for cancer in the microbial jungle.** *Genome medicine*  
Funchain, P., Eng, C.  
2013; 5 (5): 42
- **Correlation of microbiomic profiles with disease status and MDR1 methylation in head and neck squamous cell carcinoma (HNSCC).**  
Funchain, P., Bebek, G., Bennett, K. L., Burkey, B., Eng, C.  
AMER SOC CLINICAL ONCOLOGY.2012
- **Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma**  
Bebek, G., Bennett, K. L., Funchain, P., Campbell, R., Seth, R., Scharpf, J., Burkey, B., Eng, C.  
AMER ASSOC CANCER RESEARCH.2012
- **A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines** *BIOLOGICAL PROCEDURES ONLINE*  
Hesson, L. B., Packham, D., Pontzer, E., Funchain, P., Eng, C., Ward, R. L.  
2012; 14: 5
- **Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma** *HUMAN MOLECULAR GENETICS*  
Bebek, G., Bennett, K. L., Funchain, P., Campbell, R., Seth, R., Scharpf, J., Burkey, B., Eng, C.  
2012; 21 (7): 1557-1565
- **Acute liver injury induced by weight-loss herbal supplements** *WORLD JOURNAL OF HEPATOLOGY*  
Chen, G. C., Ramanathan, V. S., Law, D., Funchain, P., Chen, G. C., French, S., Shlopov, B., Eysselein, V., Chung, D., Reicher, S., Pham, B.  
2010; 2 (11): 410-415
- **Mutants with temperature-sensitive defects in the Escherichia coli mismatch repair system:: Sensitivity to mispairs generated in vivo** *JOURNAL OF BACTERIOLOGY*

- Hong, E. S., Yeung, A., Funchain, P., Slupska, M. M., Miller, J. H.  
2005; 187 (3): 840-846
- **Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets** *CANCER RESEARCH*  
Rush, L. J., Raval, A., Funchain, P., Johnson, A. J., Smith, L., Lucas, D. M., Bembea, M., Liu, T. H., Heerema, N. A., Rassenti, L., Liyanarachchi, S., Davuluri, R., Byrd, et al  
2004; 64 (7): 2424-2433
  - **In vitro and in vivo studies of MutS, MutL and MutH mutants: correlation of mismatch repair and DNA recombination** *DNA REPAIR*  
Junop, M. S., Yang, W., Funchain, P., Clendenin, W., Miller, J. H.  
2003; 2 (4): 387-405
  - **Aberrant DNA methylation in chronic lymphocytic leukemia: A role in pathogenesis?**  
Raval, A., Rush, L. J., Funchain, P., Flak, E., Davis, M., Johnson, A. J., Byrd, J. C., Plass, C.  
AMER SOC HEMATOLOGY.2002: 379A
  - ***Escherichia coli* strains (*ndk*) lacking nucleoside diphosphate kinase are powerful mutators for base substitutions and frameshifts in mismatch-repair-deficient strains** *GENETICS*  
Miller, J. H., Funchain, P., Clendenin, W., Huang, T., Nguyen, A., Wolff, E., Yeung, A., Chiang, J. H., Garibyan, L., Slupska, M. M., Yang, H. J.  
2002; 162 (1): 5-13
  - **Amplification of mutator cells in a population as a result of horizontal transfer** *JOURNAL OF BACTERIOLOGY*  
Funchain, P., Yeung, A., Stewart, J., Clendenin, W. M., Miller, J. H.  
2001; 183 (12): 3737-3741
  - **The consequences of growth of a mutator strain of *Escherichia coli* as measured by loss of function among multiple gene targets and loss of fitness** *GENETICS*  
Funchain, P., Yeung, A., Stewart, J. L., Lin, R., Slupska, M. M., Miller, J. H.  
2000; 154 (3): 959-970
  - **Temporary and Permanent Mutators lacking the mismatch repair system: The enhancement of mutators in cell populations**  
Miller, J. H., Yeung, A., Funchain, P., Mao, E., Stewart, J., Clendenin, W. M., Slupska, M. M.  
COLD SPRING HARBOR LAB PRESS.2000: 241-252